Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| P21 (Cerebrolysin Analog) | Semax | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 750 mcg-1 mg daily via intranasal administration or subcutaneous injection. | Research indicates 200-600 mcg daily via intranasal administration (0.1% solution, 2-3 drops per nostril). |
| Timing | Morning dosing preferred for cognitive effects. | Morning and early afternoon dosing (avoid evening — may cause stimulation/insomnia). Intranasal preferred for rapid CNS delivery. |
| Cycle Duration | 4-8 week cycles with 4-week rest periods. | 10-14 day cycles with equal rest periods. Some protocols use 3-5 day on / 2 day off patterns. |
| Evidence Level | animal_plus_anecdotal | moderate_human |
P21 is a tetrapeptide (DGGL — Asp-Gly-Gly-Leu) derived from the most active region of ciliary neurotrophic factor (CNTF, residues 148-151), identified through reverse engineering of Cerebrolysin. An adamantylated glycine enhances BBB permeability and metabolic stability. P21 works through LIF/STAT3 pathway inhibition, BDNF/TrkB/CREB signaling enhancement, and restoration of synaptic proteins (synaptophysin, synapsin I) and glutamate receptors. It promotes neurogenesis and maturation of newborn neurons in the dentate gyrus.
Research indicates 750 mcg-1 mg daily via intranasal administration or subcutaneous injection.
Morning dosing preferred for cognitive effects.
4-8 week cycles with 4-week rest periods.
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analog of the ACTH(4-10) fragment that rapidly upregulates brain-derived neurotrophic factor (BDNF) and its signaling receptor TrkB in the hippocampus (1.4-fold BDNF protein increase, 3-fold exon III BDNF mRNA increase). It activates dopaminergic and serotonergic brain systems, enhances neurotrophin gene expression (BDNF, NGF), and modulates intracellular calcium dynamics in brain neurons. Semax lacks ACTH's corticotropic activity, acting purely as a nootropic/neuroprotective agent.
Research indicates 200-600 mcg daily via intranasal administration (0.1% solution, 2-3 drops per nostril).
Morning and early afternoon dosing (avoid evening — may cause stimulation/insomnia). Intranasal preferred for rapid CNS delivery.
10-14 day cycles with equal rest periods. Some protocols use 3-5 day on / 2 day off patterns.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →